Sep. 24 at 8:37 PM
$TLPH meaningful progress in its NEPHRO CRRT pivotal study for its lead candidate, Niyad®. Backed by a strategic private placement (up to
$29M) led by CorMedix, the company now has financial visibility through its expected PMA submission in 2026. With FDA support that allowed a reduction in required trial size, and accelerating patient enrollment (17 enrolled as of late August), TLPH appears to be on track to deliver on key milestones. While still a binary, single-asset clinical-stage bet, its strong institutional support, defined timeline, and focus on an unmet medical need offer a compelling risk-reward profile for speculative biotech investors.
